Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational drug ASP3082 that can be given safely in people with inoperable or metastatic solid tumors that contain a mutation called KRAS G12D. ASP3082 targets the KRAS G12D mutation, blocking its ability to send signals that turn on cancer cells and cause them to grow and spread. It is given intravenously (by vein) through a central venous port on a weekly schedule.
Researchers are doing this study to see if giving LY3537982 with standard lung cancer drugs is safe and works well. The people in this study have non-small cell lung cancer that has spread. In addition, their cancers have a gene mutation (change) called KRASG12C, which can cause cancer cells to grow.
Aromatase inhibitors (AIs) are medications that interfere with estrogen production and are used to reduce the risk of breast cancer recurrence in many people with breast cancer that is fueled by estrogen. One side effect of AI treatment is a decrease in bone strength, which can lead to bones becoming weak and brittle. The bones may then break (fracture) more easily.
This purpose of this study is to assess whether adding trastuzumab/hyaluronidase-oysk or pertuzumab/trastuzumab/hyaluronidase-zzxf to the usual chemotherapy (paclitaxel and carboplatin) shrinks tumors in patients with HER2-positive endometrial serous carcinoma or carcinosarcoma.
Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.
Researchers want to see how well tivozanib plus pembrolizumab works in people with kidney cancer. The people in this study had surgery for renal cell carcinoma and have a high risk of it coming back.
Researchers are finding the best doses of valemetostat tosylate and datopotamab deruxtecan (Dato-DXd) to use in people with lung cancer. In a second part of the study, researchers are finding the best doses of valemetostat tosylate and trastuzumab deruxtecan (T-DXd) to use in people with digestive cancers.
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
Researchers in this study are assessing a combination of imaging and blood tests to find pancreatic cancer early. The people in this study have an increased risk of this cancer due to pancreatic cysts. They are planning to have surgery to remove the cysts and check them for cancer. It is hoped that the imaging and blood tests can detect pancreatic cancer early so people can avoid surgery.
